Russia’s Direct Investment Fund (RDIF) announced a deal on Tuesday with Nepal’s Trinity Pharmaceuticals to supply 25 million doses of the Sputnik-V coronavirus vaccine.
The agreement will enable 90% of Nepal’s population to get access to the Russian vaccine, according to the RDIF.
“We are excited to announce our cooperation with Russian Direct Investment Fund,” Kishor Adhikari, Director of Trinity Pharmaceuticals, said.
Russia approved the controversial Sputnik-V shot before it went to crucial Phase 3 trials, and its early approval was met with widespread concern worldwide.
“Trinity is waiting for results of the final trial of Sputnik V,” Adhikari said.
“As soon as the vaccine is approved by Government of Nepal we will make it available for the population of Nepal,” he added.